Clinical Trial Update: Bevacizumab Versus Ranibizumab for Diabetic Retinopathy [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing bevacizumab (Avastin) and ranibizumab (Lucentis) for diabetic retinopathy, including diabetic macular edema, has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetic Macular Edema
• Diabetic Retinopathy
• Proliferative Diabetic Retinopathy

Drugs mentioned

• Avastin (bevacizumab)
• Lucentis (ranibizumab)

Snippet

Sponsor: Ursula Schmidt-Erfurth, M.D. | Conditions: Diabetic Retinopathy, Diabetic Macular Edema | Phase 3 | Status: COMPLETED